Health · 6 views
Darolutamide Improves Metastasis-Free Survival in Very High-Risk Prostate Cancer
(MedPage Today) -- Adding darolutamide (Nubeqa) to androgen deprivation therapy (ADT) and radiation therapy significantly improved metastasis-free survival in patients with very high-risk prostate cancer, according to findings from the…
Summary
(MedPage Today) -- Adding darolutamide (Nubeqa) to androgen deprivation therapy (ADT) and radiation therapy significantly improved metastasis-free survival in patients with very high-risk prostate cancer, according to findings from the phase III
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Experimental ultrasound implant could help guide care after spinal cord injuryContinue reading
- STAT+: Democratic doctors and scientists ride the blue waveContinue reading
- How your brain learned to love coffee, chocolate, fat and sugarContinue reading
- Shorter Days and Dark Afternoons Can Trigger DepressionContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow